Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $84,445.04 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Najat Khan also recently made the following trade(s):

• On Monday, March 9th, Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $3.32 on Monday. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a market cap of $1.76 billion, a P/E ratio of -2.77 and a beta of 1.04. The firm’s fifty day moving average price is $3.30 and its two-hundred day moving average price is $3.81. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same period in the previous year, the company earned ($0.50) earnings per share. The company’s quarterly revenue was down 56.8% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Allworth Financial LP boosted its position in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the period. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $41,000. IFP Advisors Inc lifted its position in Recursion Pharmaceuticals by 81.5% during the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after purchasing an additional 4,650 shares during the period. Finally, Savant Capital LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $54,000. Institutional investors own 89.06% of the company’s stock.

Key Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Analyst Ratings Changes

Several research firms have commented on RXRX. Bank of America decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. reduced their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Morgan Stanley boosted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.